Fusion Pharmaceuticals Inc. (FUSN)

Market Cap	1.82B
Revenue (ttm)	2.07M
Net Income (ttm)	-94.90M
Shares Out	84.97M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	467,521
Open	21.50
Previous Close	21.49
Day's Range	21.43 - 21.51
52-Week Range	2.31 - 21.58
Beta	-0.72
Analysts	Hold
Price Target	20.86 (-2.75%)
Earnings Date	May 13, 2024

About FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2020
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: FUSN

Financial Performance

In 2023, FUSN's revenue was $2.07 million, an increase of 41.55% compared to the previous year's $1.46 million. Losses were -$94.90 million, 8.32% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for FUSN stock is "Hold." The 12-month stock price forecast is $20.86, which is a decrease of -2.75% from the latest price.

Price Target

$20.86

(-2.75% downside)

Analyst Consensus: Hold